Stocks and Investing
Stocks and Investing
Mon, April 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tony Butler Reiterated (ADAP) at Strong Buy and Held Target at $10 on, Apr 17th, 2023
Tony Butler of EF Hutton, Reiterated "Adaptimmune Therapeutics plc" (ADAP) at Strong Buy and Held Target at $10 on, Apr 17th, 2023.
Tony has made no other calls on ADAP in the last 4 months.
There is 1 other peer that has a rating on ADAP. Out of the 1 peers that are also analyzing ADAP, 0 agree with Tony's Rating of Hold.
This is the rating of the analyst that currently disagrees with Tony
- Michael Schmidt of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $5 on, Tuesday, January 3rd, 2023
Contributing Sources